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Abstract
Background: The diagnosis of multiple sclerosis (MS) is currently based solely on clinical and magnetic resonance
imaging features. However, histopathological studies have revealed four different patterns of lesion pathology in
patients diagnosed with MS, suggesting that MS may be a pathologically heterogeneous syndrome rather than a
single disease entity.
Objective: The aim of this study was to investigate whether patients with pattern I MS differ from patients with
pattern II or III MS with regard to cerebrospinal fluid (CSF) findings, especially with reference to intrathecal IgG
synthesis, which is found in most patients with MS but is frequently missing in MS mimics such as aquaporin-4-IgG-
positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein-IgG-positive
encephalomyelitis.
Methods: Findings from 68 lumbar punctures in patients who underwent brain biopsy as part of their diagnostic
work-up and who could be unequivocally classified as having pattern I, pattern II or pattern III MS were analysed
retrospectively.
Results: Oligoclonal bands (OCBs) were present in 88.2% of samples from pattern I MS patients but in only 27% of
samples from patients with pattern II or pattern III MS (P < 0.00004); moreover, OCBs were present only transiently in
some of the latter patients. A polyspecific intrathecal IgG response to measles, rubella and/or varicella zoster virus (so-called
MRZ reaction) was previously reported in 60–80% of MS patients, but was absent in all pattern II or III MS patients tested
(P < 0.00001 vs. previous cohorts). In contrast, the albumin CSF/serum ratio (QAlb), a marker of blood–CSF barrier function,
was more frequently elevated in samples from pattern II and III MS patients (P < 0.002). Accordingly, QAlb values and
albumin and total protein levels were higher in pattern II and III MS samples than in pattern I MS samples (P < 0.005,
P < 0.009 and P < 0.006, respectively).
Conclusions: Patients with pattern II or pattern III MS differ significantly from patients with pattern I MS as well as from
previous, histologically non-classified MS cohorts with regard to both intrathecal IgG synthesis and blood–CSF barrier
function. Our findings strongly corroborate the notion that pattern II and pattern III MS are entities distinct from
pattern I MS.
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Background
Histopathological studies have demonstrated at least
three different lesion patterns in early disease stages
from patients diagnosed with multiple sclerosis (MS),
termed patterns I, II and III [1, 2]. Pattern I lesions show
T cell and macrophage infiltration. Pattern II is defined
by additional antibody and complement deposition,
suggesting a contribution of humoral mechanisms to
disease pathology. Pattern III is characterized by distal
oligodendrogliopathy with dysregulated myelin protein
expression and oligodendrocyte apoptosis, but still
occurs on an inflammatory background. A fourth pat-
tern, defined by oligodendrocyte degeneration in the
periplaque white matter, has been described in few
autopsy cases of primary-progressive MS, but is rare.
These findings raise the possibility that MS, a diagnosis
currently based mainly on phenotypical, namely clinical
and radiological features [3], may in fact be a pathologic-
ally heterogeneous syndrome rather than a single disease
entity. Importantly, two recent studies demonstrated
intraindividual homogeneity and persistence of pattern I,
II and III lesions over time [4, 5], further corroborating
the notion that lesion pathology may rather define
pathogenetically distinct entities than reflect stage-
dependent processes in the development of lesions.
Intrathecal IgG synthesis, as detected qualitatively by
isoelectric focusing (IEF) of cerebrospinal fluid (CSF)
and serum or quantitatively by calculation of the
immunoglobulin CSF/serum ratio (QIgG), is present in
90–98% of MS patients, usually remains detectable over
the entire course of disease and is considered a diagnos-
tic mainstay in MS [6–9].
In this study, we retrospectively compared the CSF
profiles of patients who underwent brain biopsy as part
of their diagnostic work-up and who could be unequivo-
cally classified as having pattern I, pattern II or pattern
III lesions, respectively.
Methods
Patients
Results from 68 routine lumbar punctures in 33 patients
with histopathologically confirmed MS (16 × pattern II, 7
× pattern III, 10 × pattern I [1, 2]) were analysed for OCB
frequency and OCB patterns; CSF and serum IgG, IgM
and IgA; CSF and serum albumin; IgG, IgM and IgA CSF/
serum ratios (QIgG, QIgM, QIgA); albumin CSF/serum
ratio (QAlb); intrathecal IgG response to measles (M), ru-
bella (R) and varicella zoster (Z) (MRZ reaction [MRZR])
[10–14]; CSF total protein (TP) and CSF L-lactate levels;
and CSF white cell counts and white cell differentiation.
All patients had undergone brain biopsy as part of their
diagnostic work-up. All biopsies were histopathologically
classified at the Department of Neuropathology, Univer-
sity of Göttingen, Germany (WB, IM, FK), as previously
described [1, 2]. All patients were classified based on brain
lesions; none was classified based on brainstem, spinal
cord or optic nerve lesions. All had early active disease
and none had primary-progressive disease or pattern IV
lesions. The median age at the time of first lumbar punc-
ture was 36 years (range 13–63). The sex ratio (m:f) was
1:1.75. All patients were of Caucasian origin. Available
serum samples were retrospectively tested for aquaporin 4
(AQP4)-IgG and myelin oligodendrocyte glycoprotein
(MOG)-IgG using a cell-based assay (CBA) employing for-
malin HEK293 cells transfected with full-length human
M1-AQP4 and M23-AQP4 [15, 16] or full-length human
MOG [17, 18], respectively. All analyses were done retro-
spectively, in no case were brain, blood or CSF specimens
obtained for the present study. AQP4-IgG and MOG-IgG
testing and retrospective analysis of the patients’ CSF re-
sults was performed in an anonymized fashion.
Evaluation of the humoral immune response
Oligoclonal IgG bands (OCBs) were evaluated according
to an international consensus [9]: IEF pattern 1 = no
OCBs in CSF or serum; IEF pattern 2 = CSF-restricted
OCBs; IEF pattern 3 = CSF-restricted OCBs and
additional identical bands in CSF and serum (combin-
ation of patterns 2 and 4); IEF pattern 4 = identical
OCBs in CSF and serum (‘mirror pattern’); and IEF
pattern 5 = monoclonal bands in CSF and serum. Only
IEF patterns 2 and 3 indicate intrathecal IgG synthesis.
Quantitative expressions of the intrathecal humoral
immune response were based on calculation of the CSF/
serum ratios for IgG (QIgG), IgM (QIgM) and IgA
(QIgA) with QIg = IgCSF[mg/L]/Igserum[g/L]. The upper
limits of the respective reference ranges, Qlim(IgG),
Qlim(IgM) and Qlim(IgA), were calculated against QAlb
according to Reiber’s revised hyperbolic functions [10].
Values for QIg > Qlim(Ig) were considered to indicate
intrathecal immunoglobulin synthesis [10]. The fraction
(in %) of intrathecally produced Ig (IgIF) and the
absolute amount of locally, i.e. intrathecally, produced Ig
(IgGloc) were calculated according to the following
formulas: IgIF[%] = [QIg − Qlim(Ig)] × Igserum × 100 and
Igloc[mg/L] = [QIg − Qlim(Ig)] × Igserum, respectively [10].
Antibody indices (AI) were calculated according to
Reiber’s formula: AI = Qspec/QIgG, or AI = Qspec/Qlim(IgG)
if (Qlim > QIgG), with Qspec = IgGspec(CSF)/IgGspec(serum).
Taking into account the relatively small sample size of the
pattern I MS subgroup, we also compared the results for
pattern II and pattern III MS with data from ‘classical’ land-
mark studies on OCB and MRZR findings in (histologically
non-classified) MS [14, 19].
Evaluation of blood-CSF barrier function
The CSF/serum albumin quotient, QAlb = AlbCSF[mg/L]/
Albserum[g/L], was used to assess the blood–CSF barrier
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function. As the upper reference limit of QAlb is age
dependent, Qlim(Alb) was calculated as 4 + (a/15), with a
representing the patient’s age, according to Reiber et al.
[20]. Dysfunction of the blood–CSF barrier was defined as
QAlb > Qlim(Alb).
Cytological examination, total CSF protein and L-lactate
A white cell count >5/μL was classified as ‘increased’. An
age-dependent upper reference range for CSF L-lactate
was applied (0–15 years of age, 1.8 mmol/L; 16–50 years,
2.1 mmol/L; >50 years, 2.6 mmol/L [21, 22]). As upper
reference limit for total CSF protein, 450 mg/L was used.
Statistics
Fisher’s exact test and Mann–Whitney U test were used
to detect differences between groups. Spearman’s rho
was calculated to test for correlations. P values <0.05
were considered statistically significant. Due to the
exploratory nature of this study, no corrections for mul-
tiple comparisons were performed. Reiber diagrams were
generated using the Protein Statistics in CSF analysis
V3.0 software (Comed, Soest, Germany). The study was
approved by the institutional review boards of the Uni-
versity of Göttingen and the University of Heidelberg.
All CSF parameters evaluated in this study are routinely
tested in Germany as part of the diagnostic workup of
patients with suspected MS in Germany and are recom-
mended by the guidelines of the German Society of
Neurology and by the guidelines of the Germany Society
of CSF Analysis and Clinical Neurochemistry [21].
Results
Epidemiology and autoantibody status
Epidemiological data for all subgroups are given in Table 1.
All serum samples available for retrospective testing
(n = 13) were negative for AQP4-IgG and MOG-IgG [18].
Oligoclonal bands
CSF-restricted OCB were found in 15/17 (88.2%) samples
from patients with pattern I MS, but were negative in 27/37
(73%) of samples from patients with pattern II or pattern III
MS (P < 0.00004) (Fig. 1). Overall, only 7/22 (31.8%) pattern
II and III patients, but 8/10 (80%) pattern I MS patients,
had OCB at least once (P < 0.021). Moreover, OCBs were
only transiently positive in 2 of the 7 only OCB-positive
pattern II and III patients (patient 1, pattern II: lumbar
puncture (LP) #1 positive, LP #2 negative; patient 2,
pattern III: LP #1 positive, LP #2 negative). If only persist-
ing OCB are taken into account, only 22.7% (5/22)
patients with pattern II or III MS were positive for OCB
(P < 0.006) (Table 2). Of note, QIgG was negative at the
time of OCB determination in the two cases with transient
OCB, indicating very low levels of intrathecal IgG
synthesis in these patients. Identical OCB in serum and
CSF without additional CSF-restricted bands (the
so-called mirror pattern or IEF pattern 4), suggesting
possible systemic inflammation, were found in a
single patient with pattern II MS but were absent in
all other patients. IEF pattern 5, indicating monoclo-
nal gammopathy, was present in a single pattern II
MS patient (still detectable in a second sample taken
24 months later) and transiently in one pattern III
patient (negative follow-up sample obtained 36 days
later). Comparison of the pattern II or pattern III MS
patients’ data with data from a reference paper on
CSF in MS [19] confirmed the marked difference in
OCB frequency (P < 0.000001) (see Table 9 for
details).
IgG, IgM and IgA CSF/serum ratios
While 7/17 (41.2) samples from patients with pattern I
MS showed elevated QIgG levels, only 5/41 (12.2) of
samples from patients with pattern II or pattern III MS
did so (P < 0.021) (Table 2). Intrathecal production of
IgM as indicated by elevated QIgM was rare and was
found both in patients with pattern I MS (3/9; 33.3%)
and in patients with pattern II MS (3/12; 25%). QIgA
levels were elevated in a few pattern I patients (2/8;
25%), in a single pattern II patient and in none of the
pattern III patients (1/17; 5.9%). Data on both the
fractions and the absolute amounts of intrathecally
produced IgG, IgM and IgA can be found in Tables 2
and 3. Plots of QIgG, QIgA and QIgM, respectively,
against QAlb as a measure of blood–CSF barrier
function are shown in Fig. 2.
Table 1 Epidemiological findings
Units Pattern I MS Patterns II + III MS Pattern II MS Pattern III MS AQP4-Ab+ NMO [48]
Patients N 10 23 16 7 89
Samples N 19 49 30 19 211
Age at first LP Years 30 (13–47) 36 (20–63) 35 (20–51) 38 (26–63) 39.5 (14–79)
Sex ratio m:f 1:1 1:2.3 1:2.2 1:2.5 1:12.1
LP lumbar puncture, m male, f female
Results in AQP4-IgG-positive NMO as observed in a previous study [48] are given in the last column for comparison. Note the marked difference in the sex ratios
between pattern II MS and NMO. Years are given as median and range
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Immunoglobulin class patterns
Intrathecal Ig production, if present, was restricted to
one immunoglobulin class in most cases (cf. Table 4 for
details). A two-class immune reaction, defined as intra-
thecal production of either IgG and IgM, or IgM and
IgA, or IgG and IgA, was present in only four samples
(Table 4). None of the samples showed a three-class
immune response, defined as combined elevation of
QIgG, QIgM and QIgA. Of note, three pattern II
patients showed an isolated IgM reaction at least once
(patient 1, intrathecal IgM, IgG and IgA fractions, 83, 47
and 0%, respectively, at first lumbar puncture; 73, 0 and
0% 10 days later; and 71, 0 and 0% 14 days later; patient
2, 37, 0 and 0%; patient 3, 17, 0 and 0% at first puncture,
no intrathecal IgM, IgG and IgA synthesis at repeat
puncture at day 34 and day 815).
MRZ reaction
A positive MRZR, as defined by at least two positive
IgG-AIs, which has been reported in the literature to be
present in around 70% of patients with MS [10–14, 23],
was absent in all samples from patients with pattern II
or pattern III MS examined (P < 0.000002 compared to
unselected MS patients [23]). Only two patients with
pattern I MS had been tested for MRZR (positive in 1/2,
50%), precluding statistical comparisons. A positive AI
against at least one of the three constituents (measles
virus, rubella virus, varicella zoster virus), which has
been reported in the literature to be present in 89%
(158/177) [19] to 94% (94/100) [14] of patients with MS,
was absent in 91% (10/11) of samples from pattern II
and III patients (P < 0.000001 vs. references [19] and
[14]). MRZR was re-tested in two patients (one with
pattern II and one with pattern III MS) later in the
disease course and remained negative in both cases.
Only a single patient with pattern III MS had a posi-
tive AI for measles virus; however, a follow-up exam-
ination 1 month later was negative. See Table 5 for
details.
Blood–CSF barrier integrity
A disrupted blood–CSF barrier function was found in
only 4/17 (23.5) of samples from patients with pattern I
MS but in 30/43 (69.8) of samples from patients with
pattern II or pattern III MS (P < 0.002). Accordingly,
median QAlb values and median albumin CSF concen-
trations were higher in pattern II or III samples than in
pattern I samples (P < 0.005 for QAlb, P < 0.009 for CSF
albumin). See Table 6 for details.
Cellular immune response
CSF pleocytosis was slightly less frequent in pattern II
MS samples (6/26; 23.1%) than in pattern I (5/13; 38.5%)
and pattern III (10/14; 71.4%) samples (P < 0.02). How-
ever, median CSF white cell count (WCC) were low in
all three subgroups, with only 3/49 (6.1%) of samples
showing cell counts >40 cells/μL (see Table 7 for details).
In patients with pleocytosis, CSF white cells included
lymphocytes in all samples examined and monocytes in
most, with no significant differences between the groups.
Neutrophil granulocytes were present only in five sam-
ples from patients with pleocytosis, and the levels were
very low (1 × pattern I MS: 7 cells/μL, 5% neutrophils; 1
× pattern II MS: 6 cells/μL, 3% neutrophils; 3 × pattern
III MS: 17, 13 and 7 cells/μL, 1–3% neutrophils) and
possibly related to slight blood contamination in one
case (722 erythrocytes/μL). Eosinophils were present in
only two patients with pleocytosis (1 × pattern II MS: 69
cells/μL, 13% eosinophils, absent both in a previous
sample and in a follow-up sample, AQP4-IgG: negative;
1 × pattern III MS: 7 cells/μL, 5% eosinophils; no
erythrocytes in both cases). Sixty-two percent (13/21) of
pattern II/III MS samples without pleocytosis showed an
elevated QAlb and, thus, an albuminocytological dis-
sociation, but only 12.5% (1/8) of pattern I MS samples
(P < 0.04; see Table 7 for details).
Total CSF protein
Total protein (TP) in the CSF was more frequently
elevated in samples from patients with pattern II or III
MS samples (29/43; 67.4%) than in pattern I MS (3/15;
20%) (P < 0.003). Accordingly, median TP CSF levels
were higher in pattern II or III MS samples (median
550 mg/dl, range 168–1930) than in pattern I MS sam-
ples (median 375, range 187–750) (P < 0.006), with the
highest levels detected in pattern III samples (median
Fig. 1 Frequency of CSF-restricted oligoclonal bands (OCBs) results from 54 LPs in patients with pattern I MS compared to patients with pattern II
or pattern III MS. Note that OCBs were present only transiently in 2/7 OCB-positive pattern II/III patients
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640, range 260–1277). TP CSF levels >750 mg/dl
were present in 8/43 (18.6%) samples from patients
with pattern II or III MS, but were not detected in
any of the pattern I MS patients. As expected, TP
CSF and QAlb were strongly correlated both in the
total cohort and within each of the three subgroups
(P < 0.0001).
CSF L-lactate
A trend towards higher median L-lactate level was
noted in pattern II and III MS (1.9 mmol/L, range
0.8–3.3) compared with pattern I MS (1.3 mmol/L,
range 1.1–2.35). Similarly, a higher proportion of
patients with pattern II or III MS than patients with
pattern I MS had elevated L-lactate levels at least
once, but the difference was not statistically signifi-
cant. See Table 8 for details.
Abnormal vs. normal results
Overall, 65/68 (95.6%) LPs showed some abnormality
(either intrathecal IgG, IgM or IgA synthesis; disturbed
blood–CSF barrier function; or elevated WCC, TP or L-
lactate levels); the only three samples with normal
results were all from patients with pattern II MS.
A summary of the statistically significant differences
between groups can be found in Table 9.
Discussion
In this study, we systematically analysed the results from
68 lumbar punctures in patients who were histopatho-
logically diagnosed with pattern I, pattern II or pattern
III MS according to previously published criteria [2].
The most striking finding was the lack of intrathecal IgG
synthesis in the vast majority of samples from pattern II
or pattern III MS patients. Intrathecal IgG synthesis is
considered a diagnostic mainstay of MS. While previous
Fig. 2 CSF/serum quotient diagrams for IgG, IgM and IgA (‘Reibergrams’). Individual CSF/serum ratios of IgG, IgA and IgM are plotted against CSF/serum
albumin ratios. Values above the upper hyperbolic discrimination line, Qlim, indicate intrathecal synthesis of the respective immunoglobulin (Ig) class.
Individual intrathecal fractions, IgIF, can be directly read by interpolation from the percentiles above Qlim (median values are given in Tables 2 and 3).
Vertical dashed lines indicate the median Qlim(Alb). IgG/A/M immunoglobulin G/A/M, QIgG/A/M CSF/serum IgG/A/M ratios, QAlb CSF/serum albumin ratio
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studies reported a frequency of OCB in MS of 90–98%
in European patients, 73% of samples from pattern II or
pattern III MS patients, including all pattern III patients,
were negative in the present European cohort. Moreover,
OCBs were positive only transiently in the only two pa-
tients with non-pattern I lesions and follow-up data.
Transient OCBs have been reported in other neuroin-
flammatory diseases such as neuromyelitis optica
(NMO), acute disseminated encephalomyelitis or CNS
infection, whereas OCBs are thought to persist over the
entire disease course of MS [24, 25]. Similarly, the poly-
specific, intrathecal antiviral IgG response as defined by
at least two elevated CSF/serum antibody indices to mea-
sles, rubella and/or (so-called MRZ reaction) varicella
zoster virus, which is seen in around 70% of patients with
MS (and considered to represent non-specific bystander
B-cell activation) [10–14, 23], was missing in all patients
with pattern II or III lesions tested. Some 91% of the pat-
tern II and III MS samples did not even show a monospe-
cific IgG response to one of the constituents of the
MRZR; in contrast, a reaction to at least one of the three
viral agents has been found in 89–94% of MS patients [14,
19]. Together, this strongly suggests that patients with pat-
tern II and pattern III lesions are immunopathophysiologi-
cally distinct from patients with ‘pattern I MS’ as well as
from previous MS cohorts [8, 10, 19].
This notion is further supported by the finding of
additional, significant differences in CSF profiles be-
tween patients with pattern I lesions and patients with
pattern II or III lesions. The latter group significantly
more frequently had signs of compromised blood–CSF
barrier function, had significantly higher CSF albumin
concentrations and significantly higher and more fre-
quently elevated CSF total protein levels (Tables 6 and 9;
Fig. 3). In addition, an albuminocytological dissociation
was more commonly seen in patients with type II or III
lesions.
Although intraindividual persistence of a single lesion
type over time has been shown in a larger cohort of
biopsied patients [4, 5], there is an ongoing discussion
Table 4 Immunoglobulin class response patterns
Units Pattern I MS Pattern II + III MS Pattern II MS Pattern III MS AQP4-IgG+ NMO [48]
Three-class reaction Samples 0/16 (0) 0/32 (0) 0/21 (0) 0/11 (0) 0/87 (0%)
Two-class reaction Samples 2/16 (12.5) 2/32 (6.3) 2/21 (9.5) 0/11 (0) 5/87 (5.7%)
IgG + IgM Samples 1 1 1 0 1/87 (1.1%)
IgG + IgA Samples 1 1 1 0 1/87 (1.1%)
IgM + IgA Samples 0 0 0 0 3/87 (3.4%)
One-class reaction Samples 5/16 (31.3) 6/32 (18.8) 6/21 (28.6) 0/11 (0) 13/87 (14.9%)
Only IgG Samples 4 2 2 0 5/87 (5.7%)
Only IgM Samples 1 4 4 0 7/87 (8%)
Only IgA Samples 0 0 0 0 1/87 (1.1%)
Concentrations, ratios and fractions are reported as medians; range and total sample numbers examined are given in brackets
QIgG/A/M=CSF/serum IgG/A/M ratios
Table 5 Frequency of intrathecal IgG synthesis to infectious agents
Units MS, according to
literature [14]
Pattern
I MS
Pattern II
+ III MS
Pattern
II MS
Pattern
III MS
AQP4-IgG+ NMO
[13, 23, 43, 55, 56]
MOG-IgG+
EM [35]
MRZ reaction (≥2 AIs >1.5) Patients 72/100 (72) 1/2 (50) 0/10 (0) 0/7 (0) 0/3 (0) 1/42 (2.4) 0/11 (0)
Samples 72/100 (72) 1/2 (50) 0/12 (0) 0/8 (0) 0/4 (0) 1/42 (2.4) 0/11 (0)
M and/or R and/or Z >1.5 Samples 158/177 (89) 1/2 (50) 1/11 (9.1) 0/8 (0) 1/3 (33.3) n.d. n.d.
Measles virus AI >1.5 Samples 138/177 (78) 1/2 (50) 1/10 (10) 0/8 (0) 1/4 (25) 1/42 (2.4) 0/11 (0)
Rubella virus AI >1.5 Samples 106/177 (60) 1/2 (50) 0/9 (0) 0/8 (0) 0/4 (0) 0/42 (0) 0/11 (0)
Zoster virus AI >1.5 Samples 97/177 (55) 0/2 (0) 0/9 (0) 0/8 (0) 0/4 (0) 1/42 (2.4) 0/11 (0)
Herpes simplex virus AI >1.5 Samples 26/94 (28) n.d. 0/4 (0) 0/4 (0) 0/1 (0) n.d. n.d.
Epstein–Barr virus AI >1.5 Samples n.d. 0/2 (0) 0/2 (0) n.d. n.d. n.d. 0/2 (0)
Borrelia burgdorferi AI >1.5 Samples 0/1 (0) 0/3 (0) 0/6 (0) 0/2 (0) n.d. 0/1 (0) 0/3 (0)
Toxoplasma gondii AI >1.5 Samples n.d. 0/1 (0) 0/1 (0) n.d. n.d. n.d. 0/1 (0)
TPHA AI >1.5 Samples n.d. 0/1 (0) 0/1 (0) n.d. n.d. n.d. 0/1 (0)
n.a. not applicable AI antibody index, M measles virus, R rubella virus, TPHA Treponema pallidum haemagglutination assay, Z varicella zoster virus
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on whether the various histopathological lesion patterns
identified in MS really represent different entities or
rather different stages of the same disease. Given that
OCBs are a constant feature in MS, which once acquired
does not normally vanish [24, 25] (except in rare
patients treated with natalizumab [26, 27], a drug not
used in any of our patients), the lack of OCB positivity
or persistence in most pattern II and III patients
provides particularly strong evidence in favour of the
former hypothesis.
The term ‘multiple sclerosis’ refers to a clinicoradiolo-
gically defined syndrome. There is currently no proof
that all patients presenting with acute CNS demyelin-
ation and dissemination in time and space share the
same underlying pathogenesis. Instead, several lines of
evidence suggest that the current ‘phenotypic’ definition
of MS may cover more than one disease: (i) pathological
studies have demonstrated histopathological heterogeneity
among patients with MS [1, 4, 5]; (ii) clinical studies have
shown differences in clinical presentation (‘spinal MS’),
course (primary progressive MS without relapses vs.
relapsing-remitting MS), severity and prognosis (‘benign
MS’); (iii) MRI studies have suggested different lesion
types in MS; and (iv) treatment trials have found ‘non-
responders’, i.e. patients in whom drugs shown to be
effective in the majority of patients with MS were of no
benefit. In accordance with that hypothesis, numerous
patients previously diagnosed as having variants of MS or
‘opticospinal MS’ based on the current clinicoradiological
consensus criteria were found over the past decade to
have newly discovered humorally mediated diseases,
pathophysiologically distinct from MS, that are now termed
AQP4-IgG-positive ‘neuromyelitis optica spectrum’ dis-
order (NMOSD) [28–33] and MOG-IgG-positive enceph-
alomyelitis (EM) [17, 34–42]. Of note, many of
patients with AQP4-IgG-positive NMO or MOG-IgG-
positive EM had previously been wrongly diagnosed
with MS due to a significant overlap in clinical presentation
and clinical criteria and, in consequence, had been wrongly
treated with drugs approved for MS but not for NMO
or MOG-EM [17, 34–36, 43–47]. In a large European
cohort, more than 40% of AQP4-IgG-positive patients
with NMOSD had been previously misdiagnosed with
MS [43]. Similarly, McDonald’s clinicoradiological cri-
teria or Barkhofs’s radiological for MS were met by
33 and 15%, respectively, of all MOG-IgG-positive
Table 6 Blood–CSF barrier function and albumin levels
Units Pattern I MS Pattern II + III MS Pattern II MS Pattern III MS AQP4-IgG+ NMO [48]
QAlb > Qlim(Alb) Patients 4/10 (40) 15/22 (68.2) 9/15 (60) 6/7 (85.7) n.d.
QAlb > Qlim(Alb) Samples 4/17 (23.5) 30/43 (69.8) 16/26 (61.5) 14/17 (82.4) 75/147 (51%)
QAlb, all LPs – 4.81 (3.01–10.8; 17) 8.39 (2.1–33.9; 42) 7.3 (2.1–33.9; 25) 9 (3.3–20.7; 17) 7 (2.3–57.1; 137)
QAlb, QAlb pos. – 8.53 (6.3–10.8; 4) 9.8 (6.4–33.9; 29) 9 (6.4–33.9; 15) 10.25 (6.8––20.7; 14) 11.8 (5.63–57.14; 70)
Albumin CSF, all LPs mg/L 204 (95–517; 17) 331 (81.2–726; 41) 255.5 (81.2–599; 24) 368 (137–726; 17) 284 (83.6–1890; 139)
Albumin CSF, QAlb pos. mg/L 366 (251–517; 4) 371.5 (227–726; 28) 312 (227–599; 14) 431 (282–726; 14) 437 (219–1890)
Albumin serum, all LPs g/L 40.6 (29.3–49.5; 17) 40 (22.6–51.8; 41) 39.85 (22.6–51.4; 24) 41.2 (32.7–51.8; 17) 40.7 (19.7–67.9; 133)
Albumin serum, QAlb pos. g/L 43.15 (37.7–47.9; 4) 39.5 (22.6–50.9; 27) 35.55 (22.6–46.8; 14) 39.9 (32.7–50.9; 13) 39 (19.7–55.9)
Combined intrathecal IgG synthesis and disturbed blood–CSF barrier function
Patients, at least once N (%) 3/10 (30) 4/20 (20) 3/13 (23.1) 1/7 (14.3) n.d.
All LPs N (%) 3/17 (17.6) 5/43 (11.6) 4/26 (15.4) 1/17 (5.9) 13/74 (17.6%)
n.d. no data
QAlb = CSF/serum albumin ratio. Concentrations and ratios are reported as medians; range and total sample numbers examined are given in brackets
Table 7 CSF white cell counts
Units Pattern I MS Pattern II + III MS Pattern II MS Pattern III MS AQP4-IgG+ NMO [48]
Pleocytosis Samples 5/13 (38.5) 16/40 (40) 6/26 (23.1) 10/14 (71.4) 98/194 (50.5)
WCC, all LPs Cells/μL 5 (1–23; 13) 3 (0–267; 40) 2 (0–267; 26) 8.5 (3–24; 14) 6 (0–380; 182)
WCC, if elevated Cells/μL 11 (6–23; 5) 14.5 (6–267; 16) 40 (6–267; 6) 10.5 (7–24; 10) 19 (6–380; 98)
WCC, >40 cells/μL Samples 0/13 (0) 3/36 (8.3) 3/22 (13.6) 0/14 (0) 28/194 (14.4)
WCC, >40 cells/μL Cells/μL n.a. 69 (55–267; 3) 69 (55–267; 3) n.a. 94 (43–380; 28)
Albuminocytological
dissociation
Samples 1/8 (12.5) 13/21 (61.9) 10/18 (55.6) 3/3 (100) 27/75 (33.3)
n.a. not applicable
WCC = white cell count
WCC in the various groups are reported as medians; range and total sample numbers examined are given in brackets
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patients in a recent study [35]. Wrong diagnosis and,
accordingly, false treatment for MS may have caused
disease exacerbation and worse outcome in some of
those patients, underlining the clinical importance of
studies investigating potential heterogeneity in MS [45–47].
AQP4-IgG-positive NMO lesions, MOG-IgG-positive
EM lesions and pattern II MS lesions share important
histopathological similarities in that all three are charac-
terized by antibody and complement deposits. It is
therefore of particular note that many of the CSF find-
ings from patients with pattern II lesions were more
similar to what has been reported in AQP4-IgG-
positive NMO [43, 48, 49] and MOG-IgG-positive EM
[17, 34–36] than to what was found in patients with
pattern I lesions in our study (Tables 1, 2, 3, 4, 5, 6, 7, and 8).
However, the majority of patients with pattern II and
pattern III lesions are negative for AQP4-IgG and
MOG-IgG, as were all 10 patients with pattern II or
III lesions and available serum samples in the present
study [18, 50, 51], suggesting a potential role of other,
so far unknown autoantibodies in this condition. In
contrast, the CSF findings associated with pattern I
lesions were much more in line with what one would
expect in patients with typical MS.
Of interest, AQP4-IgG-positive NMO is characterized
by a marked female predominance (male to female ratio
~1:10–12) [43]; in contrast, the male to female ratio was
1:2.2 in the pattern II patients and thus more similar to
what has been reported in MS and in MOG-IgG-
positive EM [35].
In Germany, ≥95% of all MS patients are positive for
CSF-restricted OCB [8, 10, 19]. The fact that most pattern
II and III patients had no CSF-restricted OCB in our study
therefore implies that pattern II and III MS cannot ac-
count for the majority of patients with MS. With most
pattern II and III patients belonging to the small subgroup
of <5% of OCB-negative MS cases, pattern II MS and
pattern III MS are probably rare conditions.
This seems to be in contrast to histopathological
studies that reported a lower proportion of pattern I
cases. However, there are several reasons why pattern II
and III cases may be overrepresented in neuropatho-
logical cohorts:
(a)As OCBs are considered a hallmark of MS, it seems
reasonable to conceive that patients with clinical and
radiological findings suggestive of MS but no OCB
are more likely to undergo brain biopsy or autopsy
than those with OCB. The lack of intrathecal IgG
synthesis in patients with pattern II or pattern III
lesions may thus result in overrepresentation of
pattern II and pattern III patients in
histopathological studies.
(b)Tumefactive lesions are more commonly found in
pattern II and III patients and certainly tend to
prompt biopsies and autopsies more often than
conventional lesions. Similarly, most pattern II and
III patients in autopsy studies had died from highly
active disease (in particular, patients with pattern III
lesions, who often had died from fulminant disease
within a few months from onset). However, fulminant
and highly active disease definitely also tend to
prompt biopsy and autopsy. This may again result
in an overrepresentation of pattern II/III patients
in biopsy/autopsy studies.
(c)Some patients with pattern II lesions are positive for
MOG-IgG [4, 18, 52]. MOG encephalomyelitis shows
a strong clinical and paraclinical overlap with MS but
also significant differences such as ADEM-like presen-
tation, longitudinally extensive and bilateral ON,
longitudinally extensive myelitis [17, 34–36]. Again,
such ‘MS-atypical’ presentations may tend to prompt
Table 8 CSF total protein and CSF L-lactate
Units Pattern I MS Pattern II + III MS Pattern II MS Pattern III MS AQP4-IgG+ NMO [48]
CSF TP elevated Patients 3/9 (33.3) 14/20 (70) 8/13 (61.5) 6/7 (85.7) n.d.
CSF TP elevated Samples 3/15 (20) 29/43 (67.4) 15/26 (57.7) 14/17 (82.4) 80/152 (52.6)
CSF TP, all LPs mg/L 375 (187–750; 15) 550 (168–1930; 43) 501 (168–1930; 26) 640 (260–1277; 17) 473 (198–3620; 147)
CSF TP, if elevated mg/L 724 (532–750; 3) 622 (470–1930; 29) 571 (471–1930; 15) 693 (470–1277; 14) 780 (45.4–3620; 68)
CSF TP, >750 mg/L mg/L 0/15 (0) 8/43 (18.6) 4/26 (15.4) 4/17 (23.5) 41/147 (28)
CSF lactate elevated Patients 2/8 (25) 6/14 (42.9) 5/11 (45.5) 1/3 (33.3) n.d.
CSF lactate elevated Samples 2/9 (22.2) 7/28 (25) 6/20 (30) 1/8 (12.5) 27/83 (32.5)
CSF lactate, all LPs mmol/L 1.3 (1.1–2.35; 11) 1.9 (0.8–3.3; 28) 1.85 (0.8–3.3; 20) 1.9 (1.36–2.9; 8) 1.97 (0.87–6.8; 80)
CSF lactate, if elevated mmol/L 2.175 (2–2.35; 2) 2.5 (2.2–3.3; 7) 2.4 (2.2–3.3; 6) 2.9 (2.9–2.9; 1) 2.9 (2.1–6.8; 27)
CSF lactate, >3 mmol/L mmol/L 0/11 (0) 1/28 (3.6) 1/20 (5) 0/8 (0) 27/80 (33.8)
n.d. no data
Concentrations are reported as medians; range and total sample numbers examined are given in brackets
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Table 9 Summary of differences in CSF parameters between various MS subgroups as observed in the present study
Parameter Diagnostic groups Results P values
CSF-restricted OCB, all LPs Pattern I 15/17 (88.2) P < 0.00004
Patterns II + III 10/37 (27)
Reiber et al. [19] 262/267 (98) P < 0.000001
Patterns II + III 10/37 (27)
Pattern I 15/17 (88.2) P < 0.0001
Pattern II 9/25 (36)
Pattern III 1/12 (8.3)
CSF-restricted OCB, patients Pattern I 8/10 (80) P < 0.03
Patterns II + III 7/22 (31.8)
Reiber et al. [19] 262/267 (98) P < 0.000001
Patterns II + III 7/22 (31.8)
CSF-restricted OCB, patients, w/o transient OCBs Pattern I 8/10 (80) P < 0.006
Patterns II + III 5/22 (22.7)
Reiber et al. [19] 262/267 (98) P < 0.00001
Patterns II + III 5/22 (22.7)
MRZ reaction (≥2 AIs >1.5), all LPs Jarius et al. [23] 397/546 (69) P < 0.000001
Patterns II + III 0/12 (0)
M and/or R and/or Z >1.5, all LPs Reiber et al. [19] 158/177 (89) P < 0.000001
Patterns II + III 0/12 (0)
QIgG > Qlim(lgG), all LPs Pattern I 7/17 (41.2) P < 0.03
Patterns II + III 5/41 (12.2)
QAlb > Qlim(Alb), all LPs Pattern I 4/17 (23.5) P < 0.002
Patterns II + III 30/43 (69.8)
Pattern I 4/17 (23.5) P = 0.002
Pattern II 16/26 (61.5)
Pattern III 14/17 (82.4)
QAlb, all LPs Pattern I 4.81 (3.01–10.8; 17) P < 0.005
Patterns II + III 8.39 (2.1–33.9; 42)
Albumin CSF, all LPs Pattern I 204 (95–517; 17) P < 0.009
Patterns II + III 331 (81.2–726; 41)
Total CSF protein elevated, all LPs Pattern I 3/15 (20) P < 0.003
Patterns II + III 29/43 (67.4)
Total CSF protein, all LPs Pattern I 375 (187–750; 15) P < 0.007
Patterns II + III 550 (168–1930; 43)
Albuminocytological dissociation, all LPs Pattern I 1/8 (12.5) P < 0.04
Patterns II + III 13/21 (61.9)
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biopsy or autopsy and, thus, artificially increase the
proportion of pattern II cases in biopsy/autopsy
studies.
Our results indicate that the proportion of patients
with type II and type III lesions may be particularly high
among OCB-negative patients diagnosed with MS.
While only 2–10% of patients with MS are negative for
OCB according to the literature, this subset is not small
in absolute numbers, given the high prevalence of MS in
some Western populations (e.g. ~2.3 million patients
worldwide; ~140,000 patients in Germany). Given that
fact and considering that differences in pathophysiology
may well translate into different treatment requirements,
as already shown in AQP4-IgG-positive NMO [47] and
suggested for MOG-IgG-positive EM [34, 35], studies
aiming at enhancing our understanding of the immuno-
pathophysiology of pattern II and III lesions seem highly
warranted.
Importantly, the frequency of OCB has been reported
to increase with latitude [53, 54]. Whether this implies a
higher proportion of patients with ‘pattern I’ lesions at
higher latitudes is currently unknown but deserves to be
addressed in future studies.
We acknowledge that our study has both strengths and
limitations. While we count the high number of CSF
samples included (n = 68) and the high number of CSF
parameters analysed among the strengths of our study, the
retrospective and exploratory study design is a potential
limitation. However, prospective studies would be ex-
tremely difficult or even impossible to perform given that
brain biopsies are only very rarely performed in patients
with MS and that lumbar puncture is not anymore re-
quired to make the diagnosis of MS according to the
current international diagnostic criteria [3].
Conclusions
In summary, the present study provides additional,
strong evidence for pattern I MS on the one hand and
pattern II MS and pattern III MS on the other hand
being distinct entities by demonstrating significant dif-
ferences in CSF findings between patients with pattern
I lesions and patients with pattern II or pattern III le-
sions, especially with regard to intrathecal IgG synthe-
sis. Of particular note, the CSF profiles present in the
pattern II/III subgroup were more similar to those re-
ported in AQP4-IgG-positive NMO and MOG-IgG-
positive EM than to those classically considered typical
for MS. Further studies are now warranted to confirm
our findings in larger, international cohorts. Such stud-
ies need to take into account the recently reported in-
crease in frequency of CSF oligoclonal banding in MS
with latitude [53, 54].
Fig. 3 Albumin CSF/serum ratios, CSF albumin concentrations, and
CSF total protein concentrations. QAlb CSF/serum albumin ratio
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